Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Operating Margin (2017 - 2025)

Crinetics Pharmaceuticals has reported Operating Margin over the past 9 years, most recently at 2169.55% for Q4 2025.

  • Quarterly results put Operating Margin at 2169.55% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 6714.77% (up 2589870.0% YoY), and the annual figure for FY2025 was 6714.77%, up 2589870.0%.
  • Operating Margin for Q4 2025 was 2169.55% at Crinetics Pharmaceuticals, up from 99710.49% in the prior quarter.
  • Over the last five years, Operating Margin for CRNX hit a ceiling of 1080.39% in Q1 2022 and a floor of 99710.49% in Q3 2025.
  • Median Operating Margin over the past 5 years was 9646.51% (2022), compared with a mean of 16546.14%.
  • Peak annual rise in Operating Margin hit 822463bps in 2025, while the deepest fall reached -1937120bps in 2025.
  • Crinetics Pharmaceuticals' Operating Margin stood at 2865.31% in 2021, then plummeted by -134bps to 6707.48% in 2022, then crashed by -154bps to 17045.38% in 2023, then dropped by -22bps to 20747.62% in 2024, then soared by 90bps to 2169.55% in 2025.
  • The last three reported values for Operating Margin were 2169.55% (Q4 2025), 99710.49% (Q3 2025), and 12522.99% (Q2 2025) per Business Quant data.